These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37273950)

  • 1. Real-life Effectiveness of Omalizumab in Patients with Severe Allergic Asthma: RELIEF Study.
    Al Ahmad M; Borboa Olivares LM; Cardoso AP; Djazmati W; Vinuesa MA; Domínguez MJG; Neto AC; Gamboa LU; Lee JK; Pinho N; Tassinari P
    Open Respir Med J; 2022; 16():e187430642206130. PubMed ID: 37273950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Long-Term Effectiveness and Safety of Omalizumab on Patient- and Physician-Reported Asthma Control: A Three-Year, Real-Life Observational Study.
    Schreiber J; Schwab Sauerbeck I; Mailänder C
    Adv Ther; 2020 Jan; 37(1):353-363. PubMed ID: 31741282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients.
    Arrobas A; Barbosa MP; Rabiais S; Vandewalle B; Félix J
    Pulmonology; 2021; 27(2):124-133. PubMed ID: 32247710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The "real-world" effectiveness and safety of omalizumab in patients with uncontrolled persistent allergic asthma in Slovakia: a subgroup analysis of the eXpeRience study.
    Siracká S; Tinková LD; Hochmuth L; Leščišinová H; Hrubiško M; Dostálová K; Jeseňák M
    Postepy Dermatol Alergol; 2023 Feb; 40(1):134-141. PubMed ID: 36909923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies.
    Bousquet J; Humbert M; Gibson PG; Kostikas K; Jaumont X; Pfister P; Nissen F
    J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2702-2714. PubMed ID: 33486142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omalizumab in Children with Severe Allergic Asthma: The Italian Real-Life Experience.
    Licari A; Castagnoli R; Denicolò C; Rossini L; Seminara M; Sacchi L; Testa G; De Amici M; Marseglia GL;
    Curr Respir Med Rev; 2017 Mar; 13(1):36-42. PubMed ID: 29213221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study.
    Brusselle G; Michils A; Louis R; Dupont L; Van de Maele B; Delobbe A; Pilette C; Lee CS; Gurdain S; Vancayzeele S; Lecomte P; Hermans C; MacDonald K; Song M; Abraham I
    Respir Med; 2009 Nov; 103(11):1633-42. PubMed ID: 19619998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia.
    Torres-Duque CA; Ocampo-Gómez J; Castillo MM; Cano-Rosales D; Giraldo-Montoya Á; Rodríguez F; Palacios-Ortega I; Durán-Silva M; Reynales H; García E;
    BMC Pulm Med; 2022 Nov; 22(1):447. PubMed ID: 36437461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
    Norman G; Faria R; Paton F; Llewellyn A; Fox D; Palmer S; Clifton I; Paton J; Woolacott N; McKenna C
    Health Technol Assess; 2013 Nov; 17(52):1-342. PubMed ID: 24267198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world effectiveness and safety of omalizumab in patients with uncontrolled severe allergic asthma from the Czech Republic.
    Kirchnerová OR; Valena T; Novosad J; Teřl M;
    Postepy Dermatol Alergol; 2019 Feb; 36(1):34-43. PubMed ID: 30858777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-life efficacy and safety of omalizumab in Portuguese patients with persistent uncontrolled asthma.
    Pereira Barbosa M; Bugalho de Almeida A; Pereira C; Chen CW; Georgiou P; Peachey G;
    Rev Port Pneumol (2006); 2015; 21(3):151-6. PubMed ID: 25926246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does omalizumab make a difference to the real-life treatment of asthma exacerbations?: Results from a large cohort of patients with severe uncontrolled asthma.
    Grimaldi-Bensouda L; Zureik M; Aubier M; Humbert M; Levy J; Benichou J; Molimard M; Abenhaim L;
    Chest; 2013 Feb; 143(2):398-405. PubMed ID: 23505637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.
    Burch J; Griffin S; McKenna C; Walker S; Paton J; Wright K; Woolacott N
    Pharmacoeconomics; 2012 Nov; 30(11):991-1004. PubMed ID: 22950547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting.
    Suzuki C; Lopes da Silva N; Kumar P; Pathak P; Ong SH
    J Med Econ; 2017 Aug; 20(8):832-839. PubMed ID: 28532191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
    Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
    J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of omalizumab in children and adolescents with uncontrolled allergic asthma: a case series from Poland.
    Sztafińska A; Gwardys M; Podlecka D; Mospinek E; Stelmach I
    Postepy Dermatol Alergol; 2021 Jun; 38(3):427-432. PubMed ID: 34377123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of omalizumab in severe, persistent IgE-mediated asthma in pediatric and adult patients: a real-world observational study in Egyptian population.
    Tarraf HN; Masoud HH; Zidan M; Wahba B
    J Asthma; 2020 Feb; 57(2):160-166. PubMed ID: 30592242
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of individual allergen sensitization on omalizumab treatment outcomes in patients with severe allergic asthma determined using data from the Czech Anti-IgE Registry.
    Vaník P; Novosad J; Kirchnerová O; Krčmová I; Teřl M;
    Allergy Asthma Clin Immunol; 2020; 16():81. PubMed ID: 32944035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study.
    Bhutani M; Yang WH; Hébert J; de Takacsy F; Stril JL
    PLoS One; 2017; 12(8):e0183869. PubMed ID: 28859150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term post-marketing study in Japan.
    Adachi M; Kozawa M; Yoshisue H; Lee Milligan K; Nagasaki M; Sasajima T; Miyamoto T; Ohta K
    Respir Med; 2018 Aug; 141():56-63. PubMed ID: 30053973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.